Repurposing of gallium‐based drugs for antibacterial therapy
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
While the occurrence and spread of antibiotic resistance in bacterial pathogens is vanishing current anti‐infective therapies, the antibiotic discovery pipeline is drying up. In the last years, the repurposing of existing drugs for new clinical applications has become a major research area in drug discovery, also in the field of anti‐infectives. This review discusses the potential of repurposing previously approved gallium formulations in antibacterial chemotherapy. Gallium has no proven function in biological systems, but it can act as an iron‐mimetic in both prokaryotic and eukaryotic cells. The activity of gallium mostly relies on its ability to replace iron in redox enzymes, thus impairing their function and ultimately hampering cell growth. Cancer cells and bacteria are preferential gallium targets due to their active metabolism and fast growth. The wealth of knowledge on the pharmacological properties of gallium has opened the door to the repurposing of gallium‐based drugs for the treatment of infections sustained by antibiotic‐resistant bacterial pathogens, such as Acinetobacter baumannii or Pseudomonas aeruginosa,and for suppression of Mycobacterium tuberculosis growth. The promising antibacterial activity of gallium both in vitro and in different animal models of infection raises the hope that gallium will confirm its efficacy in clinical trials, and will become a valuable therapeutic option to cure otherwise untreatable bacterial infections. © 2014 BioFactors, 40(3):303–312, 2014
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shannon, R. D. (1976) · Acta Crystallographica Section A · doi:10.1107/s0567739476001551 · Cited by 66,145
Siderophore-Based Iron Acquisition and Pathogen Control
Miethke, M., & Marahiel, M. A. (2007) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00012-07 · Cited by 1,774 · cited 2×
“However, the generation of broadspectrum and effective antimicrobial compounds targeting iron acquisition mechanisms or exploiting siderophore-mediated drug delivery (“Trojan horse” approach) is often difficult, due to the species-specificity of many iron-uptake systems [77], their redundancy in bacterial genomes [78,…”
BackgroundChemistry and biology of siderophores
Hider, R. C., & Kong, X. (2010) · Natural Product Reports · doi:10.1039/b906679a · Cited by 1,722 · cited 1×
“However, the generation of broadspectrum and effective antimicrobial compounds targeting iron acquisition mechanisms or exploiting siderophore-mediated drug delivery (“Trojan horse” approach) is often difficult, due to the species-specificity of many iron-uptake systems [77], their redundancy in bacterial genomes [78,…”
BackgroundIron availability and infection
Weinberg, E. D. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.07.002 · Cited by 516 · cited 1×
“However, iron is scarcely bioavailable for the majority of bacteria due to its poor solubility in neutral aqueous solutions under aerobic conditions, and is even less accessible to bacterial pathogens due to sequestration by iron-chelating proteins within the host (for example, Tf and Lf) [58,59].”
BackgroundBacterial transferrin and lactoferrin receptors
Gray-Owen, S. D., & Schyvers, A. B. (1996) · Trends in Microbiology · doi:10.1016/0966-842x(96)10025-1 · Cited by 299
Discovery of a Siderophore Export System Essential for Virulence of Mycobacterium tuberculosis
Wells, R. M., Jones, C. M., Xi, Z., Speer, A., Danilchanka, O., Doornbos, K. S., Sun, P., Wu, F., Tian, C., & Niederweis, M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003120 · Cited by 267
Garcia, E. C., Brumbaugh, A. R., & Mobley, H. L. T. (2011) · Infection and Immunity · doi:10.1128/iai.01222-10 · Cited by 256 · cited 1×
“However, the generation of broadspectrum and effective antimicrobial compounds targeting iron acquisition mechanisms or exploiting siderophore-mediated drug delivery (“Trojan horse” approach) is often difficult, due to the species-specificity of many iron-uptake systems [77], their redundancy in bacterial genomes [78,…”
BackgroundNew insights into the metal specificity of the Pseudomonas aeruginosa pyoverdine–iron uptake pathway
Braud, A., Hoegy, F., Jezequel, K., Lebeau, T., & Schalk, I. J. (2009) · Environmental Microbiology · doi:10.1111/j.1462-2920.2008.01838.x · Cited by 246
Gallium Disrupts Iron Metabolism of Mycobacteria Residing within Human Macrophages
Olakanmi, O., Britigan, B. E., & Schlesinger, L. S. (2000) · Infection and Immunity · doi:10.1128/iai.68.10.5619-5627.2000 · Cited by 220
Cited by
Metals to combat antimicrobial resistance
Frei, A., Verderosa, A. D., Elliott, A. G., Zuegg, J., & Blaskovich, M. A. T. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00463-4 · Cited by 638
Bioactive Glasses: Where Are We and Where Are We Going?
Baino, F., Hamzehlou, S., & Kargozar, S. (2018) · Journal of Functional Biomaterials · doi:10.3390/jfb9010025 · Cited by 525
New Antimicrobial Strategies Based on Metal Complexes
Claudel, M., Schwarte, J. V., & Fromm, K. M. (2020) · Chemistry · doi:10.3390/chemistry2040056 · Cited by 344
Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections
Wagner, S., Sommer, R., Hinsberger, S., Lu, C., Hartmann, R. W., Empting, M., & Titz, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01698 · Cited by 258
Metadata
- Authors
- Bonchi, C., Imperi, F., Minandri, F., Visca, P., & Frangipani, E.
- Venue
- BioFactors
- Publisher
- Wiley
- Published
- 2014-02-14
- Volume
- 40
- Issue
- 3
- Pages
- 303-312
- ISSN
- 0951-6433 (ISSN-L)
- 1872-8081
- OpenAlex
- W2125102767
- Cited by
- 138
- References
- 9
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Repurposing of gallium‐based drugs for antibacterial therapy. https://app.cochat.ai/papers/10.1002/biof.1159
- The paper
- Bonchi, C., Imperi, F., Minandri, F., Visca, P., & Frangipani, E. (2014). Repurposing of gallium‐based drugs for antibacterial therapy. BioFactors. https://doi.org/10.1002/biof.1159
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.